Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Combo Chidamide-Rituximab Shows Synergy in DLBCL

Key clinical point: Pre-clinical data suggests the novel histone deacetylase (HDAC) inhibitor chidamide could be effective in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) being retreated with rituximab.

Major finding: Combined therapy with rituximab and chidamide showed inhibited tumor growth and rituximab-induced cell death in both in vivo and in vitro models.

Study details: A pre-clinical study examining the effects of chidamide as a novel HDAC inhibitor in DLBCL.

Disclosures: The study was funded by the National Natural Science Foundation of China and the Kay Kendall Leukaemia Fund, UK. The authors reported having no conflicts of interest.


Guan XW et al. Cell Death Dis. 2020 Jan 6. doi: 10.1038/s41419-019-2210-0.